📋 PROMIS NEUROSCIENCES INC. (PMN) - Financial Results
Filing Date: 2026-05-12
Accepted: 2026-05-12 06:45:26
Event Type: Financial Results
Event Details:
PROMIS NEUROSCIENCES INC. (PMN) Reports the reporting period Financial Results
PROMIS NEUROSCIENCES INC. (PMN) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: Not disclosed
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: $75
anticipated in early Q3 2026
anticipated in early 2027
targeting of toxic misfolded proteins in neurodegenerative diseases that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of Aß are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity, and the ability of the Company’s cash runway to fund operations through 2027
📋 PROMIS NEUROSCIENCES INC. (PMN) - Financial Results
Filing Date: 2026-05-12
Accepted: 2026-05-12 06:45:26
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: